Web Watch
Web Watch in One Page
The five active monitors below are calibrated to the durable thesis variables identified in the report, not the next quarterly headline. The verdict is Lean Long, Wait For Confirmation: the cyclical recovery evidence (Q1 2026 beat, Florida sole-source, golden cross) is real, but the 5-to-10-year underwriting case depends on three things the market is not yet pricing — Washington's Medicaid RFP retention, the cadence of OBBBA Medicaid work-requirement implementation, and whether FY25 reserves were set light. Two monitors (Washington RFP, OBBBA implementation) watch the durable revenue-pool question. One (MCR + prior-period development) watches the cycle verdict. One (Florida ramp + new contract pipeline) watches whether the moat actually held through the trough. One (capital allocation + credibility) watches whether the board recalibrated after the FY24-25 debt-funded peak buybacks and whether the Hindlemann credibility overhang lifts. Together they target the three disagreements with consensus that the report most relies on.
Active Monitors
| Rank | Watch item | Cadence | Why it matters | What would be detected |
|---|---|---|---|---|
| 1 | Washington RFP and top-4 state Medicaid contract outcomes | Weekly | Long-term thesis driver #1 (RFP incumbency). Washington is $4.2B / 13% of Medicaid premium; a loss combined with the Virginia precedent rebases the moat reading from compounding to eroding. | WA HCA Apple Health re-procurement filings, named-bidder lists, scoring changes, MOH or competitor wins/losses in WA / CA / NY / TX / IL / OH, and competitor displacements in MOH-incumbent states. |
| 2 | OBBBA work-requirement implementation and Medicaid rate adequacy | Weekly | Failure mode #2. Determines whether the post-OBBBA Expansion pool shrinks 15% (mgmt mid) or 20%+ (bear). Also captures CY2027 state rate-trend notices — the only mechanism that closes the rate-vs-trend gap. | State-level OBBBA implementation rule filings, KFF tracker shifts, CMS guidance, provider-tax-cap changes, and CY2027 Medicaid rate notices in CA, NY, TX, WA that move the implied attrition path or rate-trend gap. |
| 3 | Through-cycle MCR cadence and prior-period reserve adequacy | Daily | Long-term thesis driver #3 (through-cycle 88-89% MCR). Tests whether the FY26 guide of 92.9% is hittable and whether the FY25 reserve set was adequate. | Quarterly consolidated and segment MCR vs the 91.7% / 92.6% benchmarks, Days in Claims Payable moves outside 44-50 days, FY26 10-K Note 10 prior-period development disclosure, retroactive Medicaid premium adjustments in CA / TX / NY. |
| 4 | Florida sole-source go-live and new-store contract pipeline | Weekly | Validates whether the moat held through the trough. Florida (~$5-6B, ~120k members) is the largest single new-store contribution to the embedded-earnings construct; hot new-store MCR would break the bridge. | Florida Q4 2026 go-live milestones, Illinois HealthChoice 1/1/2027 ramp, new-state contract wins or shortlists, tuck-in acquisitions, new-store MCR cadence, and any goodwill-impairment trigger on acquired plans. |
| 5 | Capital allocation discipline, credibility ledger and insider cadence | Daily | Long-term thesis driver #5 plus failure modes #4 (Hindlemann), #5 (CEO succession) and #6 (subsidiary capital). Tests whether the board has recalibrated after $2.1B of FY24-25 buybacks at ~$375 avg vs ~$198 today. | Buyback pacing and average price paid, new debt issuance funding buybacks, subsidiary dividend coverage, Form 4 insider activity (especially the CLO), Hindlemann MTD ruling, CEO succession or contract extension, and the 2026 say-on-pay vote outcome. |
Why These Five
The report's most important open question is whether the 5-to-10-year revenue pool the moat protects settles near $40-42B or grinds down to $35-37B — the variable that decides whether normalized EPS is $20+ (re-rate to 13x) or $13-15 (re-rate to 9-11x). Monitors 1 and 2 are pointed directly at that question: Washington RFP outcomes update the moat reading, and OBBBA state-level implementation updates the pool size. Monitor 3 watches the cycle verdict — the convergence point where bull and bear cases meet — but is framed on the durable through-cycle MCR variable and the FY26 10-K prior-period development disclosure, not the next earnings beat. Monitor 4 watches whether the moat actually delivers operating economics on the new contracts won during the worst year. Monitor 5 watches the governance and capital-allocation discipline that determines whether owner value compounds even if the cycle plays out as bulls expect. Together these are the five questions the report says actually move the underwriting case; the next earnings print moves the tape but does not, by itself, resolve any of them.